The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 3, 2010, Pages 493-500

  Liang, Jun ^a   Jiang, Tao ^a   Yao, Ru Yong ^a   Liu, Zi Min ^a   Lv, Hong Ying ^a   Qi, Wei Wei ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

ERCC1; Metastatic colorectal cancer; Oxaliplatin; Polymorphism; XRCC1

Indexed keywords

CAPECITABINE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINATE CALCIUM; OXALIPLATIN; XRCC1 PROTEIN; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; PLATINUM COMPLEX; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CODON; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; COLORECTAL TUMOR; DISEASE COURSE; GENETICS; GENOTYPE; LYMPHOCYTE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CODON; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENOTYPE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77954677109     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1186-3     Document Type: Article

References (33)

1. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW (2005) Colorectal cancer. Lancet 365(9454):153-165
2. Midgley R, Kerr D (1999) Colorectal cancer. Lancet 353:391-399
3. Punt CJ (2004) New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 15:1453-1459
4. Ries L A G, Melbert D, Krapcho M et al (2007) SEER Cancer Statistics Review, 1975-2004. National Cancer Institute, Bethesda, MD. Available at http://seer.cancer.gov/csr/1975-2004/. Accessed 15 November 2007
5. De Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947
6. Kelly H, Goldberg RM (2005) Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23:4553-4560
7. Raymond E, Chaney SG, Taamma A et al (1998) Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9:1053-1071
8. Raymond E, Faivre S, Chaney S et al (2002) Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1:227-235
9. Rosell R, Mendez P, Isla D (2007) Platinum resistance related to a functional NER pathway. J Thorac Oncol 2(12):1063-1066
10. Gossage L, Madhusudan S (2007) Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 33(6):565-577
11. Fortini P, Pascucci B, Parlanti E et al (2003) The base excision repair: mechanisms and its relevance for cancer susceptibility. Biochimie 85(11):1053-1071
12. Horton JK, Watson M, Stefanick DF et al (2008) XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res 18(1):48-63
13. Yu JJ, Mu C, Lee KB et al (1997) A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res Genomics 382:13-20
14. Sorenson MA, Kurland CG, Pederson S et al (1989) Codon usage determines translation rate in Escherichia coli. J Mol Biol 207:365-377
15. Kimchi-Sarfaty C, Oh JM, Kim IW et al (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-528 (Pubitemid 46175758)
16. Martin LP, Hamilton TC, Schilder RJ (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14(5):1291-1295
17. Sharma RA, Dianov GL (2007) Targeting base excision repair to improve cancer therapies. Mol Aspects Med 28 (3-4): 345-374
18. Kweekel DM, Gelderblom H, Guchelaar HJ et al (2005) Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31:90-105
19. Yu JJ, Lee KB, Mu C et al (2000) Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 16:555-560
20. Kamikozuru H, Kuramochi H, Hayashi K, Nakajima G, Amamoto M (2008) ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy. Int J Oncol 32:1091-1096
21. Tibaldi C, Giovannetti E, Vasile E, Mey V et al (2008) Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in capecitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14:1797-1803
22. Smith S, Su D, Rigault de la Longrais IA et al (2007) ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 25(33):5172-5179
23. Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin C, Ducreux M, Sarasin A, Praz F (2005) ERCC1 codon 118 polymorphism s a predictive factor for the tumor response to oxaliplatin/5-Xuorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11:6212-6217
24. Martinez-Balibrea E, Abad A, Aranda E et al (2008) Pharmacogenetic approach for capecitabine or 5-Xuorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer 44:1229-1237
25. Ruzzo A, Graziano F, Loupakis F et al (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25(10):1247-1254
26. Lindahl T, Lood RD (1999) Quality control by DNA repair. Science 286:1897-1905
27. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz H-J (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344-354
28. Liu B, Wei J, Zou Z, Qian X, Nakamura T, Zhang W, Ding Y, Feng J, Yu L (2007) Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 15:1049-1053
29. Colhoun HM, McKeigue PM, Davey Smith G et al (2003) Problems of reporting genetic associations with complex outcomes. Lancet 361:865-872
30. Huang ZH, Hua D, Du X et al (2009) Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol 64(5):1001-1007
31. Li WQ, Zhang L, Ma JL et al (2009) Association between genetic polymorphisms of DNA base excision repair genes and evolution of precancerous gastric lesions in a Chinese population. Carcinogenesis 30(3):500-505
32. Kim HS, Kim MK, Chung HH et al (2009) Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol 113:264-269
33. Improta G, Sgambato A, Bianchino G et al (2008) Polymorphisms of the DNA repair genes XRCC1 and XRCC3 and risk of lung and colorectal cancer: a case-control study in a Southern Italian population. Anticancer Res 28 (5 B): 2941-2946